Recruiting

Observational Study

Sponsor:

Neuronetics

Code:

NCT06917339

Conditions

Depression

Obsessive-Compulsive Disorder

Anxiety Depression

Eligibility Criteria

Sex: All

Age: 5 - 70+

Healthy Volunteers: Not accepted

Interventions

NeuroStar Advanced TMS Therapy System

Study Details

Brief summary:

In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.

Conditions

Depression

Obsessive-Compulsive Disorder

Anxiety Depression

Study ID

NCT06917339

Start date

Feb 25, 2025

Status verified date

Apr, 2026

Completion date

Dec, 2035

Anticipated

Primary completion date

Dec, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 5 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female reported in database and not an invalid entry
  • Age reported and not an invalid entry
  • Treatment date of November 01, 2008 or later.

Exclusion Criteria:

• Incomplete information on treatment parameters

Study Design

Enrollment

156000 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients treated with NeuroStar TMS

Interventions

NeuroStar Advanced TMS Therapy System

non-invasive brain stimulation device

Primary outcome measure

  • Change in clinical assessment score from baseline to post-treatment [ Time Frame: 8 weeks ]

Central Contacts and Locations

Central contacts

Neha Goyal

763-528-1599neha.goyal@neurostar.com

Eleanor Cole, PhD

415-724-7960Eleanor.cole@neurostar.com

Locations

Neuronetics

Recruiting

Malvern, Pennsylvania, United States, 19355

More Information

Sponsor

Neuronetics

Last update posted

Apr 9, 2026

Last verified

Apr, 2026

Keywords

  • TMS

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Neuronetics on 2026-04-09.